The purpose of this study is to determine if giving the medicine "heparin" intravenously (through the veins) continuously for up to 14 days to subjects after a brain aneurysm has burst will help improve the chances of subjects having a good recovery after the bleed compared to subjects who get routine brain aneurysm care (standard of care). Patients who get routine care would also get heparin, but they would typically get an overall lower dose and the heparin would be injected under the skin (heparin shot) instead of in the veins.
Sickle cell disease (SCD) is a genetic blood disorder present at birth characterized by painful vaso-occlusive episodes. Pain episodes typically result in approximately one to two severe pain crises requiring hospitalization per year along with another ten pain episodes managed at home. Pain crises can emerge as early as six to twelve months and most children with the most common form of the disease (HbSS), experience a pain episode requiring hospital care by the age of five years. Promoting better coping with pain in preschool age children likely requires additional adaptation of methods and consideration of a developmental framework. Very young children have limited coping skills, a limited ability to communicate pain, and it is up to the primary caregiver to correctly interpret and treat the pain that a child may be experiencing. Despite the frequency of painful episodes early in life in SCD, there has been little work to-date addressing pain management in young children with SCD. Management of pain episodes early in life by parents may be an important developmental context for later child and family coping with pain, as well as coping with other aspects of this chronic health condition. Consequently, the current study will target parents of preschool age children with SCD through an online video-based platform in order to teach pain management skills to help to identify and manage SCD-related pain episodes.
This research study is designed to examine the effects of a single treatment of electroacupuncture (EA) on shoulder pain and range of motion in patients who have ben diagnosed with shoulder impingement syndrome. Patients with shoulder impingement syndrome will be recruited from orthopedic and physical therapy offices in Charleston, SC. If they are determined to be eligible for the study, the patients will receive informed consent. If the patient chooses to participate in the study, they will have their shoulder pain and range of motion in their shoulder assessed. The patient will then receive one treatment of EA. EA is a roughly 15 minute acupuncture-like procedure where thin needles (about the diameter of a thick human hair) will be placed in the muscle tissue surrounding your shoulder. A small electric current will be applied to the needles while they are inserted. Generally, acupuncture does not hurt. Some people feel the needles as they go in, and some people feel nothing Following the treatment, the patient will have their shoulder pain and range of motion assessed again.
This is a registry to investigate the outcomes of participants with commercially available Boston Scientific neurostimulators for pain. This study will also assess the economic value and technical performance of these devices for pain.
Chronic opioid therapy for pain can be associated with significant risks, and a significant number of patients maintained on chronic opioids have continued pain and/or poor functioning. When patients need to or want to come off their opioid pain medications, there is little to guide physicians as to how to best help them do so, and it is not known how patients do after coming off opioid medications. The goals of this study are (1) to evaluate two medications in assisting patients in coming off their opioid pain medications and (2) determining outcomes after discontinuing opioids.
This study is to evaluate the effects of cognitive behavorial therapy in combination with tDCS (transcranial direct current stimulation) improving chronic pain and functionality, reducing severity of opioid use disorders, improve sleep, and reducing impairment in associated mental health areas (e.g., depression, anxiety, PTSD).
This study will investigate whether a new medical technology can help reduce post-operative pain in patients undergoing total knee or total hip replacements. The new technology is called Transcranial Direct Current Stimulation (tDCS) and uses a very small amount of electricity to temporarily stimulate specific areas of the brain. The electrical current passes through the skin, scale, hair, and skull and can temporarily increase or decrease activity in the areas of the brain that are thought to be involved in pain reduction. The tDCS sessions last 20 minutes, and patients will be asked to report pain ratings. This study in specific hopes to determine optimal tDCS dosing parameters before tDCS will become a viable clinical intervention for post-operative pain across surgical specialties.
The purpose of this study is to collect and evaluate clinical and radiographic outcomes data on patients who have undergone, or will undergo, shoulder replacement surgery. Patients who receive a device from the Equinoxe® Shoulder System, manufactured and distributed by Exactech, Inc as well as patients who receive a device from another shoulder arthroplasty system may be included in this study.